Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
ACGT awards $500,000 to advance immunotherapy approach for treating solid tumors

ACGT awards $500,000 to advance immunotherapy approach for treating solid tumors

Salk Institute uses $1 million gift to support world class cancer researcher

Salk Institute uses $1 million gift to support world class cancer researcher

New glioma-targeted nano-therapeutic offers a potential treatment for glioblastomas

New glioma-targeted nano-therapeutic offers a potential treatment for glioblastomas

Scientists discover new immunotherapy target for malignant brain tumors

Scientists discover new immunotherapy target for malignant brain tumors

New zebrafish model could help advance glioblastoma multiforme research

New zebrafish model could help advance glioblastoma multiforme research

A novel approach to suppress the growth of glioblastoma cells

A novel approach to suppress the growth of glioblastoma cells

Study reveals detailed map of glioblastoma in genetic, molecular detail

Study reveals detailed map of glioblastoma in genetic, molecular detail

Scientists avert drug resistance in subtype of brain tumors

Scientists avert drug resistance in subtype of brain tumors

New combination treatment approach improves overall survival in mice with glioblastoma

New combination treatment approach improves overall survival in mice with glioblastoma

New drug candidate to be trialed for most lethal form of brain cancer

New drug candidate to be trialed for most lethal form of brain cancer

Sodium fluorescein may improve the safety and outcomes of vestibular schwannoma surgery

Sodium fluorescein may improve the safety and outcomes of vestibular schwannoma surgery

New method could provide additional insight into brain tumors

New method could provide additional insight into brain tumors

New cellular pathway limits growth and spread of brain tumors

New cellular pathway limits growth and spread of brain tumors

Recurring glioblastomas with very few mutations are far more vulnerable to immunotherapies

Recurring glioblastomas with very few mutations are far more vulnerable to immunotherapies

Study: 20% of glioblastomas are fueled by overactive mitochondria

Study: 20% of glioblastomas are fueled by overactive mitochondria

Nuclear DICER complex disrupts cytoplasmic microRNAome in glioblastoma cancer cells

Nuclear DICER complex disrupts cytoplasmic microRNAome in glioblastoma cancer cells

Heat treatment during chemotherapy is more effective at destroying cancer cells

Heat treatment during chemotherapy is more effective at destroying cancer cells

Tissue healing after brain injury could spur tumor growth

Tissue healing after brain injury could spur tumor growth

Molecular reporters produce fluorescence to expose the allies of tumor cells

Molecular reporters produce fluorescence to expose the allies of tumor cells

Anti-diarrhea drug triggers cell death in glioblastoma cells

Anti-diarrhea drug triggers cell death in glioblastoma cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.